Search results

50 results

Sorted by Relevance . Sort by Date

  1. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

  2. Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

    Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children

  3. Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)

    Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older

  4. EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)

    Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules

  5. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)

    Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease

  6. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (TA772)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies

  7. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    Evidence-based recommendations on selpercatinib (Retsevmo) for previously treated RET fusion-positive advanced non-small-cell lung cancer in adults

  8. Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults

  9. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of EGFR mutation positive non small cell lung cancer in adults after complete

  10. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)

    Evidence-based recommendations on tucatinib (TUKYSA) for HER2 positive locally advanced or metastatic breast cancer in adults after 2 or more anti HER2 treatment therapies

  11. Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

    Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable

  12. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer

  13. Cabotegravir with rilpivirine for treating HIV-1 (TA757)

    Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological

  14. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults

  15. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable

  16. Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

    Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable

  17. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)

    Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy

  18. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults

  19. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)

    Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor

  20. Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA776)

    Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults

  21. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults

  22. Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults

  23. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

    Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults

  24. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

    Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults

  25. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)

    Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults

  26. Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)

    Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults

  27. Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment

  28. Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)

    Evidence-based recommendations on tepotinib (Tepmetko) for treating advanced non-small-cell lung cancer (NSCLC) with MET gene alterations in adults

  29. Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) (TA793)

    NICE is unable to make a recommendation on anifrolumab (Saphnelo) for active autoantibody-positive systemic lupus erythematosus. This is because AstraZeneca did not provide an evidence submission. We will review this decision if the company decides to make a submission

  30. Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)

    Evidence-based recommendations on diroximel fumarate (Vumerity) for active relapsing–remitting multiple sclerosis in adults

  31. Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)

    NICE is unable to make a recommendation on enfortumab vedotin (Padcev) for previously treated locally advanced or metastatic urothelial cancer. This is because Astellas did not provide an evidence submission. We will review this decision if the company decides to make a submission

  32. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)

    Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults